Abbott's SonicForce IVL system shows strong 30-day results cracking coronary artery calcium in study.

Abbott announced positive 30-day results from the TECTONIC study of its investigational SonicForce Coronary Intravascular Lithotripsy (IVL) System, which uses acoustic waves to break calcium in coronary arteries. The study of 335 patients met safety and effectiveness goals with a 0.3% target lesion failure rate and 97% procedural success, indicating the system's potential to improve treatment of severe coronary calcification. This technology could enhance stent placement by preparing vessels more effectively, addressing a major challenge in coronary artery disease treatment. Abbott aims for regulatory approval to add SonicForce to its cardiovascular device portfolio.

Abbott's promising clinical trial results for the SonicForce IVL System highlight ongoing innovation in cardiovascular treatment. On Pluang, Abbott Laboratories (ABT) shares are trading at USD 106.24, up 1.60% as of Nov 02, 2026 04:01 WIB. The stock holds a market cap of $183.77 billion and offers a dividend yield of 2.37%, reflecting steady investor interest in this health sector leader.